Songjiang Ma - 14 Aug 2024 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Reporting relationship: President, Director
Issuer ticker: GYRE
Reported as of: 14 Aug 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Aug 2024, 21:01:34 UTC
Prior SEC filing: 22 Nov 2023
Next SEC filing: 19 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Ruoyu Chen, as attorney-in-fact for Songjiang Ma

Key filing fact

Songjiang Ma filed Form 4 for GYRE THERAPEUTICS, INC. (GYRE) on 16 Aug 2024.

Key facts

This page summarizes Songjiang Ma's Form 4 filing for GYRE THERAPEUTICS, INC. (GYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Aug 2024, 21:01.

Change

Previous filing in this sequence was filed on 22 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GYRE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +26,000
Change %
Price: $0.000000
Shares after: 26,000
Date: 14 Aug 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,000
Exercise price: $9.98
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through August 14, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date.